Kalypsys has multiple, structurally diverse, preclinical stage candidates which are positioned as development backups to KD3010.
Combination therapy with PPARδ and PPARγ agonists single agents in rodent models of diabetes support the notion that PPAR /γ mixed agonists will demonstrate superior insulin sensitization with reduced side effects compared to activation of PPARγ alone.
Kalypsys has identified novel, preclinical stage, dual PPARδ/γ agonists for the treatment of diabetes and dyslipidemia.
Additional approaches to discover novel treatments for diabetes are being taken by Kalypsys. These include the identification of small molecules that modulate the action of the glucagon-like peptide 1 (GLP-1). GLP-1 is a peptide hormone that stimulates glucose-dependent insulin secretion and insulin synthesis, inhibits glucagon secretion and gastric emptying, and reduces food intake.